Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (398)

Latest Posts

About This Stock More About This Stock
Biotechs Running Again: Life Science Stocks
Article By: Rod Raynovich
Tuesday, April 25, 2017 11:59 PM EDT
Biotechs are running again taking the cue from Nasdaq which is up 3.44% in April after a brief mid-month sell-off. Biotech stocks rallied from global macro concerns which has dampened investor enthusiasm over the past two months.
In this article: BMY, FBIOX, IBB, QQQ, AMGN, GILD, XBI, XLV, ABBV, BLUE, FMI Also: RHHBY, BIIB
Read
HH Better Big Pharma Dividend Stock: AbbVie Or Gilead?
Article By: SureDividend
Tuesday, April 18, 2017 12:04 PM EDT
Gilead could provide stronger returns than AbbVie, if the company can stabilize earnings and return to growth. The stock is extremely cheap based on valuation.
In this article: GILD, ABBV Also: ABT
Read
Biotech In A Doldrums: Rallies Interrupted By Geopolitics, Trump Agenda And Flight To Safety
Article By: Rod Raynovich
Tuesday, April 11, 2017 7:38 PM EDT
Recent geopolitical news has created a backdrop that has discouraged investors in biotech who were already risk averse from drug pricing issues. There has been little momentum over since mid-march with choppy sluggish trading.
In this article: RHHBY, IBB, ILMN, GILD, HOLX, VRTX, XBI, XLV, BLUE
Read
Week In Review: Zai Lab Partners With GE On China Biologics Manufacturing
Article By: ChinaBio® Today
Saturday, April 8, 2017 5:23 PM EDT
This week in China biotech features a partnership with GE Healthcare in biologic drug manufacturing and the South Korea government launching a multi-million dollar fund to encourage biotech startups.
In this article: GILD
Read
E Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Article By: Abba's Aces
Friday, March 24, 2017 5:52 PM EDT
Gilead is advancing a Crohn's treatment to Phase 2 but even if it passes Phase 3, it won't be the solution to GILD's problems..
In this article: GILD Also: GLPG
Read

PARTNER HEADLINES

Latest Tweets for $GILD

No tweets yet!

$GILD

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kurt Benson 3/24/2017 10:12:59 PM

I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.

www.talkmarkets.com/.../interview-with-vitality-biopharma-inc

Not a lot of info on the company though.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kirk Sheffield 3/24/2017 10:11:55 PM

I think $GILD will rebound. This isn't the only product they have in their pipeline.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Alpha Stockman 3/24/2017 10:07:45 PM

I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.

Gilead Sciences Receives Canadian Approval For HIV Drug
David Reynolds 2/20/2017 10:04:11 PM

The opening up of this market for #GileadSciences should bode well for the stock $GILD.

Gilead Sciences: Cheap Growth Or Value Trap?
Karen Klein 9/13/2016 5:39:48 PM

Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD

3 Cult Stocks To Avoid In 2015
Bruce Powers 1/26/2015 8:01:06 AM

Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 6:09:51 PM

Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 4:48:08 PM

I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.

1 to 8 of 8 comments